NCT07441460 2026-03-02
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
Clinical Trials
8 trialsNCT07424287 2026-02-20
A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Not yet recruiting
NCT06829199 2026-02-19
MK-5890-003
Merck Sharp & Dohme LLC
Phase 2 Withdrawn
NCT06291064 2026-02-17
TARMAC
University of Chicago
Phase 2 Recruiting
NCT06144944 2026-01-30
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Active not recruiting
NCT07320508 2026-01-21
EIC-SNACC
Eye & ENT Hospital of Fudan University
Phase 2 Recruiting
NCT04290793 2026-01-07
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2/3 Active not recruiting
NCT04872985 2026-01-06
Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Active not recruiting